Areteia Therapeutics is a clinical-stage biotech focused on developing oral inflammation and immunology therapies, initially targeting severe eosinophilic asthma with dexpramipexole. Dexpramipexole is an oral small-molecule eosinophil maturation inhibitor that lowered blood eosinophil counts in Phase II testing and was well tolerated. The company has initiated late-stage development, running three Phase III trials in partnership with Population Health Partners’ development unit, Validae Health. Areteia was created by Population Health Partners and Knopp Biosciences and is backed by a syndicate led by Bain Capital Life Sciences alongside other life-sciences and strategic investors. Financially, Areteia has secured up to $425 million in Series A commitments after an additional $75 million expansion, strengthening its capitalization to support late-stage development and commercial supply. Planned uses of proceeds include expanding Phase III development into Japan and additional global markets, expanding manufacturing, and life-cycle management such as a once-daily formulation. Areteia Therapeutics was launched to develop dexpramipexole, a first-in-class oral eosinophil maturation inhibitor and the company’s lead drug candidate. Dexpramipexole is described as an oral small molecule that inhibits maturation and release of eosinophils and is in Phase 3 development for eosinophilic asthma. In a Phase 2 study, dexpramipexole produced a significant, dose-dependent reduction in blood absolute eosinophil counts and was well tolerated with no serious adverse events or discontinuations. Areteia plans to conduct late-stage development including Phase 3 clinical trials, secure commercial supply, and pursue potential next-generation medicines. The company was created by Population Health Partners and Knopp Biosciences and will partner with Population Health Partners’ Validae Health unit on the development program. Jorge Bartolome has been appointed CEO and a board including representatives from Knopp, Bain Capital Life Sciences, Population Health Partners, and Arch Ventures will oversee the company.

Total raised

$425M

Funding rounds

2

Latest round

Series A

Latest activity

Feb 2024